2 recruiting, 1 active not recruiting, 1 completed. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow COMPASS Pathways: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder COMP360 psilocybin - PTSD - Post Traumatic Stress Disorder, PTSD | Phase 2 / Phase 3 | Recruiting | COMPASS Pathways | 300 | 2026-09-01 | 2026-10-23 |
| The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder Psilocybin - Major Depressive Disorder | Phase 3 | Recruiting | Sharmin Ghaznavi | 20 | 2024-09-10 | 2026-08-13 |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Psilocybin - Treatment Resistant Depression | Phase 3 | Active not recruiting | COMPASS Pathways | 572 | 2023-02-14 | 2026-08-10 |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Psilocybin - Treatment Resistant Depression | Phase 3 | Completed | COMPASS Pathways | 258 | 2023-01-24 | 2026-08-10 |
Depressive Disorder, Treatment-Resistant (2) · Combat Disorders (1) · Depressive Disorder, Major (1) · Stress Disorders, Post-Traumatic (1) · Wounds and Injuries (1)
Psilocybin (3)
United States (4) · Canada (2) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Ireland (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)